Selected article for: "dna technology and recombinant dna technology"

Author: Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua
Title: Antibody Engineering for Pursuing a Healthier Future
  • Document date: 2017_3_28
  • ID: 0fegsm1v_50
    Snippet: The first fully human mAb was developed over 25 years ago by phage display and a selection of antigen-specific binders from blood lymphocyte libraries (Gavilondo and Larrick, 2000) . This technique employed transgenic animals such as mice and rabbits with integrated human immunoglobulin (Ig) loci. Germline-configured chimeric constructs confirmed that human, mouse, and all mammalian Ig loci function in very similar ways (Neuberger and Bruggemann,.....
    Document: The first fully human mAb was developed over 25 years ago by phage display and a selection of antigen-specific binders from blood lymphocyte libraries (Gavilondo and Larrick, 2000) . This technique employed transgenic animals such as mice and rabbits with integrated human immunoglobulin (Ig) loci. Germline-configured chimeric constructs confirmed that human, mouse, and all mammalian Ig loci function in very similar ways (Neuberger and Bruggemann, 1997) . Antibody development has progressed from hybridoma technology to a recombinant deoxyribonucleic acid (DNA) approach. In the last few years, a number of engineered antibody drugs have been approved or investigated in phase II or III clinical trials ( Table 3 ; Nelson et al., 2010; Dantas-Barbosa et al., 2012; Nixon et al., 2014) .

    Search related documents:
    Co phrase search for related documents